查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018601

罕見疾病基因檢測市場：2026-2032年全球市場預測（依檢測類型、技術、疾病、應用及最終用戶分類）

Rare Disease Genetic Testing Market by Test Type, Technology, Disease Indication, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，罕見疾病基因檢測市場價值將達到 17.9 億美元，到 2026 年將成長至 20.9 億美元，到 2032 年將達到 53.9 億美元，複合年成長率為 17.00%。

主要市場統計數據
基準年 2025 17.9億美元
預計年份：2026年 20.9億美元
預測年份：2032年 53.9億美元
複合年成長率 (%) 17.00%

策略性展望，概括了罕見疾病基因檢測的現狀，闡述了技術成熟度、臨床實施壓力以及相關人員的優先事項。

罕見疾病基因檢測處於快速技術創新、不斷演進的臨床方案以及患者和臨床醫生對精準診斷日益成長的期望的交匯點。本文概述了影響診斷、臨床和研究生態系統中相關人員策略和投資決策的關鍵要素。此外，本文也重點介紹了關鍵促進因素，例如定序平台的成熟、基因組數據在臨床工作流程中的整合，以及對罕見疾病患者早期準確診斷的日益重視。

技術進步、整合的臨床工作流程和實證夥伴關係如何重塑罕見疾病基因檢測的提供和分發？

罕見疾病基因檢測領域正經歷一場變革，其驅動力包括平台創新、跨診療路徑的整合以及新型實證模型的湧現。新一代定序平台不斷拓展診斷的整體性，而微陣列和聚合酵素鏈鎖反應(PCR) 方法在需要進行標靶、經濟高效的檢測時仍然發揮著至關重要的作用。同時，生物資訊流程和變異解讀框架也在不斷發展，透過提供更快、更具臨床意義的報告，減少臨床醫生和患者的困惑。

2025 年美國關稅變化對罕見疾病基因檢測相關人員的供應鏈、採購和成本動態的營運和策略影響。

美國將於2025年引入並實施關稅，這將為罕見疾病基因檢測供應鏈中的相關企業帶來一系列營運和策略方面的考量。關稅措施可能改變進口試劑、定序設備及相關實驗室耗材的相對成本結構，進而對診斷實驗室和生產商的利潤率造成壓力。這種壓力將促使相關人員重新審視籌資策略、合約條款和庫存政策，以維持服務的連續性和成本競爭力。

透過整合對技術、測試方法、最終用戶、應用和目標疾病的全面見解，我們制定有針對性的市場策略。

在罕見疾病基因檢測領域，了解市場區隔對於目標產品開發、商業策略制定和臨床整合至關重要。技術細分將微陣列、新一代定序和聚合酵素鏈鎖反應(PCR) 區分為三大主要平台類別。在新一代定序中，有不同的調查方法，例如連接定序 (SBL) 和合成定序 (SBS)，每種方法都會影響通量、讀長和平台特有的化學反應。聚合酵素鏈鎖反應(PCR) 在標靶檢測中仍然不可或缺，分為數位 PCR 和定量 PCR 兩種方法。它們具有不同的靈敏度和定量特性，因此適用於確認性檢測和監測。

影響美洲、歐洲、中東和非洲以及亞太地區採用、監管和供應鏈選擇的趨勢和戰略考量。

區域趨勢對罕見疾病基因檢測生態系中的臨床部署模式、監管預期和供應鏈設計有顯著影響。在美洲，人們高度重視將基因組診斷整合到醫院和門診診療流程中，公立和私立機構都在尋求臨床效用和運作可擴展性的證據。此外，該地區擁有活躍的本土製造業和密集的診斷實驗室網路，這些網路都體現在部署計劃和合作機會中。

競爭格局分析重點在於用於市場差異化的平台整合、生物資訊優勢、臨床證據產生和營運可擴展性。

罕見疾病基因檢測領域的競爭格局由技術供應商、設備製造商、診斷實驗室和臨床服務供應商組成。主要企業憑藉其平台性能、生物資訊能力以及全面的臨床解讀服務脫穎而出，這些服務能夠支援在複雜的診斷環境中部署。平台提供者與診斷實驗室之間的策略合作能夠加速臨床檢驗和規模化應用，而與研究機構的合作則有助於證據產生和新應用領域的研發。

為產業領導者提供可操作的策略重點，以增強韌性、加速臨床部署，並在罕見疾病基因檢測中展現可衡量的價值。

業界領導者應採取一系列切實可行的優先事項，以增強罕見疾病基因檢測的韌性，加速其應用，並最大限度地發揮其臨床影響力。首先，投資建構模組化、可互通的資訊學框架將有助於快速解讀突變、促進機構間資料共用，並確保符合不斷發展的報告標準。其次，與策略供應商建立合作關係，並建立區域製造夥伴關係關係，將有助於降低關稅和供應鏈風險，同時提高採購計畫的確定性。第三，優先透過有針對性的前瞻性研究和真實世界數據（REW）舉措來建立臨床證據，將有助於減少與保險公司和醫院採購委員會之間的障礙，從而增強報銷準備。

採用透明且可重複的調查方法，結合對關鍵相關人員的訪談、二手資料的整合以及嚴格的檢驗，以獲得可靠的市場洞察。

本報告的調查方法整合了多種證據來源，旨在對罕見疾病基因檢測現況進行穩健且可重複的分析。主要研究包括對診斷實驗室、醫院、研究機構和專科診所的相關人員進行結構化訪談，以及與平台和試劑生產商進行專家諮詢。次要研究則整合了同儕審查文獻、監管指導文件和臨床實踐指南，以闡明各項技術的性能、臨床效用和實施限制。

為了實現罕見疾病基因檢測的臨床價值，我們需要解決策略挑戰，降低營運風險，並整合夥伴關係方式。

總之，罕見疾病基因檢測正處於一個轉折點，隨著技術的成熟和供應鏈監管的日益嚴格，其發展與不斷變化的臨床預期交織在一起。平台創新、更完善的解讀框架以及針對性證據的產生正在推動臨床應用的普及，而監管和報銷的複雜性則要求制定細緻入微、因地制宜的策略。價格壓力帶來了短期至中期的營運挑戰，同時也凸顯了在地化和供應鏈多元化的長期機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：罕見疾病基因檢測市場：依檢測類型分類

  • EXOME定序
    • 臨床EXOME
    • 研究EXOME
  • 基因組定序
    • 標靶基因組
    • 全基因組
  • 面板檢查
    • 癌症小組
    • 心血管小組
    • 神經系統面板
  • 單基因檢測

第9章：罕見疾病基因檢測市場：依技術分類

  • 微陣列
  • 下一代定序
    • 連接定序
    • 合成定序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 定量PCR

第10章：罕見疾病基因檢測市場：依疾病分類

  • 血液疾病
  • 代謝性疾病
    • 酵素缺乏
    • 粒線體疾病
  • 神經肌肉疾病
  • 腫瘤學

第11章：罕見疾病基因檢測市場：依應用領域分類

  • 攜帶者篩檢
  • 診斷
  • 新生兒篩檢
  • 產前篩檢
    • 侵入性
    • 非侵入性
  • 研究用途

第12章：罕見疾病基因檢測市場：依最終用戶分類

  • 診斷檢測實驗室
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構
  • 專科診所

第13章：罕見疾病基因檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 罕見疾病基因檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 罕見疾病基因檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國罕見疾病基因檢測市場

第17章：中國罕見疾病基因檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3billion, Inc.
  • Ambry Genetics Corporation
  • Arup Laboratories
  • Baylor Genetics
  • Caris Life Sciences
  • CENTOGENE NV
  • Color Health, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • GeneDx, LLC
  • Genomelink, Inc.
  • Helix OpCo, LLC
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Invitae Corporation
  • Laboratory Corporation Of America Holdings
  • Macrogen, Inc.
  • Myriad Genetics, Inc.
  • Nonacus Limited
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • Progenity, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Realm IDX, Inc.
  • Sanofi SA
  • The Cooper Companies, Inc.
  • Thermo Fisher Scientific Inc.
  • Variantyx, Inc.
Product Code: MRR-B9334AD6C623

The Rare Disease Genetic Testing Market was valued at USD 1.79 billion in 2025 and is projected to grow to USD 2.09 billion in 2026, with a CAGR of 17.00%, reaching USD 5.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.79 billion
Estimated Year [2026] USD 2.09 billion
Forecast Year [2032] USD 5.39 billion
CAGR (%) 17.00%

A strategic orientation to the rare disease genetic testing landscape that frames technology maturation, clinical adoption pressures, and stakeholder priorities

Rare disease genetic testing sits at the intersection of rapid technological innovation, evolving clinical protocols, and growing expectations from patients and clinicians for precise diagnostics. This introduction frames the essential elements that shape strategy and investment decisions for stakeholders across the diagnostic, clinical, and research ecosystems. It outlines prevailing drivers such as the maturation of sequencing platforms, the integration of genomic data into clinical workflows, and the heightened emphasis on earlier and more accurate diagnosis for rare disease populations.

The landscape is defined by an expanding repertoire of test modalities and applications, which in turn demand integration with laboratory information systems, regulatory compliance frameworks, and reimbursement pathways. As innovations reduce technical barriers, adoption decisions hinge increasingly on diagnostic yield, turnaround time, and alignment with clinical pathways. This introduction therefore orients readers to the structural forces and operational priorities that inform subsequent analysis, setting expectations for how technological choices, application areas, and end-user needs will be explored in depth throughout the report.

How converging technological advances, integrated clinical workflows, and evidence-driven partnerships are reshaping rare disease genetic testing delivery and adoption

The rare disease genetic testing field is undergoing transformative shifts driven by platform innovation, integration across care pathways, and the emergence of new evidence-generation models. Next generation sequencing platforms are pushing the frontier of diagnostic comprehensiveness while microarray and polymerase chain reaction methods retain critical roles where targeted, cost-effective testing is needed. Concurrently, bioinformatics pipelines and variant interpretation frameworks are evolving to deliver faster, more clinically actionable reports, reducing ambiguity for clinicians and patients.

Operational transformations are also evident in how tests are delivered: diagnostic laboratories are adopting hybrid workflows that combine broad genomic screens with targeted confirmatory assays, and specialty clinics are embedding genetic counselors within care teams to improve patient outcomes. On the payer side, value-based conversations are shifting reimbursement toward diagnostics that demonstrably shorten diagnostic odysseys or enable effective therapeutic selection. As a result, the industry is witnessing an acceleration of partnerships across technology providers, clinical networks, and research institutions to scale evidence generation, standardize reporting, and de-risk clinical implementation pathways.

Operational and strategic consequences of the United States tariff changes in 2025 on supply chains, sourcing, and cost dynamics for rare disease genetic testing stakeholders

The prospect and implementation of tariffs in the United States during 2025 have introduced a series of operational and strategic considerations for organizations involved in rare disease genetic testing supply chains. Tariff measures can alter the relative cost structure of imported reagents, sequencing instruments, and ancillary laboratory consumables, creating margin pressures for diagnostic laboratories and manufacturers alike. These pressures incentivize stakeholders to reassess sourcing strategies, contract terms, and inventory policies to preserve service continuity and cost-competitiveness.

In response, supply chain optimization becomes a central management imperative. Organizations may accelerate qualification of alternative suppliers, prioritize regional manufacturing partnerships, or increase buffer inventories for critical reagents and components. These adjustments have implications for procurement lead times, working capital, and pricing negotiations. Moreover, tariff-driven cost shifts can influence clinical adoption patterns by changing the delivered price of tests to end users and payers, thereby affecting the economic calculus for hospitals, specialty clinics, and diagnostic laboratories. Over the medium term, the tariff environment also encourages strategic investment in domestic production and localization of key manufacturing activities to enhance resilience and reduce exposure to cross-border policy volatility.

Comprehensive segmentation-driven insights that align technology, test modalities, end users, applications, and disease indications to inform targeted market strategies

Understanding segmentation is essential for targeted product development, commercial strategy, and clinical integration in the rare disease genetic testing domain. Technology segmentation distinguishes microarray, next generation sequencing, and polymerase chain reaction as core platform categories. Within next generation sequencing there are distinct methodological pathways represented by sequencing by ligation and sequencing by synthesis, each of which impacts throughput, read length, and platform-specific chemistry considerations. Polymerase chain reaction remains indispensable for targeted assays and is split into digital PCR and quantitative PCR approaches, offering differing sensitivity and quantitation profiles that make them suitable for confirmatory testing or monitoring.

Test type segmentation further refines clinical and commercial positioning with exome sequencing, genome sequencing, panel tests, and single gene tests forming the principal categories. Exome sequencing divides into clinical exome and research exome modalities that emphasize clinical-grade interpretation versus broader exploratory discovery. Genome sequencing differentiates between targeted genome approaches and whole genome methodologies, which carry different implications for data volume, interpretation complexity, and incidental finding management. Panel tests are specialized into oncology, cardiovascular, and neurological panels, reflecting disease-focused diagnostic pathways, while single gene tests remain relevant for high-yield, phenotype-driven diagnostic scenarios.

End-user segmentation clarifies where adoption and workflow integration efforts should focus. Diagnostic laboratories, hospitals, research institutions, and specialty clinics each present distinct procurement cycles, validation expectations, and implementation constraints. Within hospitals, the split between private and public institutions influences budgetary flexibility, procurement timelines, and reimbursement environments. Application segmentation shows clinical use cases such as carrier screening, diagnostics, newborn screening, prenatal screening, and research applications, with prenatal screening further differentiated into invasive and non-invasive approaches that carry divergent clinical workflows and counseling requirements. Disease indication segmentation highlights hematological disorders, metabolic disorders, neuromuscular disorders, and oncology as prioritized clinical areas, with metabolic disorders further divided into enzyme deficiencies and mitochondrial disorders that require tailored testing and interpretation strategies.

Taken together, these segmentation lenses enable precise go-to-market strategies, tailored clinical evidence generation, and focused engagement with specific end-user audiences. They also inform prioritization of regulatory pathways, reimbursement negotiations, and laboratory validation programs that align with the technical and clinical requirements of each segment.

Regional dynamics and strategic considerations for Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption, regulation, and supply chain choices

Regional dynamics materially influence clinical adoption patterns, regulatory expectations, and supply chain design in the rare disease genetic testing ecosystem. In the Americas, there is a pronounced emphasis on integrating genomic diagnostics into hospital and outpatient care pathways, with both private and public institutions seeking evidence of clinical utility and operational scalability. This region also exhibits active domestic manufacturing and a dense network of diagnostic laboratories, which informs adoption timetables and partnership opportunities.

Europe, the Middle East & Africa presents a mosaic of regulatory regimes and reimbursement models that necessitate region-specific clinical validation and health-economic evidence. Fragmentation across national health systems requires tailored market entry strategies and collaborations with local diagnostic laboratories and specialty clinics to navigate differing coverage policies and clinical guidelines. In the Asia-Pacific region, investment in genomics infrastructure is accelerating, driven by both public health initiatives and private sector innovation. Diverse adoption drivers across major markets emphasize newborn and prenatal screening programs in some jurisdictions and research-driven sequencing initiatives in others, creating opportunities for localized partnerships, technology transfer, and capacity-building programs. Across all regions, cross-border collaborations, harmonized variant interpretation standards, and investments in workforce development are critical levers to expand access and ensure high-quality clinical implementation.

Competitive landscape analysis emphasizing platform integration, bioinformatics strength, clinical evidence generation, and operational scalability for market differentiation

Competitive dynamics in the rare disease genetic testing arena are characterized by a mix of technology vendors, instrument manufacturers, diagnostic laboratories, and clinical services providers. Leading players differentiate through platform performance, bioinformatics capabilities, and the depth of clinical interpretation services that support adoption in complex diagnostic settings. Strategic partnerships between platform providers and diagnostic laboratories accelerate clinical validation and scale, while collaborations with research institutions support evidence generation and pipeline development for emerging applications.

Companies that prioritize integrated offerings-combining robust sequencing chemistry, scalable informatics, and streamlined laboratory workflows-are positioned to reduce friction in clinical adoption. Similarly, organizations investing in quality management systems, accreditation, and clinician-facing decision support tools are better able to meet the stringent requirements of hospital procurement processes and specialty clinics. Market entrants that focus on niche clinical applications or on delivering cost-effective confirmatory assays can win adoption within targeted care pathways, particularly where reimbursement pathways exist or where clinical utility is demonstrable. Overall, competitive success depends on an interplay of technological excellence, regulatory compliance, clinical evidence, and the ability to operationalize services at scale.

Actionable strategic priorities for industry leaders to build resilience, accelerate clinical adoption, and demonstrate measurable value in rare disease genetic testing

Industry leaders should adopt a set of actionable priorities to strengthen resilience, accelerate adoption, and maximize clinical impact in rare disease genetic testing. First, investing in modular, interoperable informatics frameworks will facilitate rapid variant interpretation, cross-institutional data sharing, and compliance with evolving reporting standards. Second, establishing strategic supplier relationships and regional manufacturing partnerships can mitigate tariff and supply chain risks while improving procurement predictability. Third, prioritizing clinical evidence development through targeted prospective studies and real-world evidence initiatives will reduce barriers with payers and hospital procurement committees, thereby increasing reimbursement preparedness.

Leaders should also enhance engagement with clinical end users by embedding genetic counseling capacity and clinician education programs to support interpretation and downstream care. Additionally, tailoring go-to-market strategies to the specific requirements of private versus public hospital systems, as well as research institutions and specialty clinics, will improve conversion rates and operational alignment. Finally, implementing flexible pricing models and value-based agreements aligned to clinical outcomes can differentiate offerings and support broader access to testing services, while simultaneously demonstrating commitment to measurable patient benefit.

Transparent and reproducible methodology combining primary stakeholder interviews, secondary literature synthesis, and rigorous triangulation for defensible market insights

The research methodology underpinning this report integrates multiple evidence streams to produce a robust, reproducible analysis of the rare disease genetic testing environment. Primary research included structured interviews with stakeholders across diagnostic laboratories, hospitals, research institutions, and specialty clinics, combined with expert consultations with platform and reagent manufacturers. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, and clinical practice guidelines to contextualize technology performance, clinical utility, and implementation constraints.

Analytical methods incorporated a segmentation-based approach to examine differences by technology, test type, end user, application, and disease indication. Regional analyses were informed by policy reviews and stakeholder input to capture regulatory and reimbursement nuances. Triangulation of findings across primary interviews and secondary sources ensured that insights reflect both operational realities and emerging trends. Data validation processes included cross-checks with multiple expert respondents and reconciliation of conflicting inputs through additional inquiry, yielding a balanced and defensible set of conclusions to support strategic decision-making.

Synthesis of strategic imperatives, operational risk mitigation, and partnership approaches to realize the clinical promise of rare disease genetic testing

In conclusion, rare disease genetic testing is at an inflection point where technological maturity converges with evolving clinical expectations and heightened supply chain scrutiny. The combined effect of platform innovation, more sophisticated interpretation frameworks, and targeted evidence generation is expanding clinical uptake, while regulatory and reimbursement complexities necessitate nuanced, region-specific strategies. Tariff-related pressures introduce short- to medium-term operational challenges but also surface longer-term opportunities for localization and supply chain diversification.

Decision-makers should consider a dual focus on strengthening internal capabilities-such as informatics, quality systems, and clinical engagement-and on forging external partnerships that accelerate validation and market access. By aligning product development and commercial strategies to the segmented needs of different technologies, test types, end users, and disease indications, organizations can prioritize high-impact opportunities and mitigate execution risk. The trajectory of the field favors those who can harmonize scientific excellence with pragmatic operational approaches and clear demonstration of clinical value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rare Disease Genetic Testing Market, by Test Type

  • 8.1. Exome Sequencing
    • 8.1.1. Clinical Exome
    • 8.1.2. Research Exome
  • 8.2. Genome Sequencing
    • 8.2.1. Targeted Genome
    • 8.2.2. Whole Genome
  • 8.3. Panel Test
    • 8.3.1. Cancer Panels
    • 8.3.2. Cardiovascular Panels
    • 8.3.3. Neurological Panels
  • 8.4. Single Gene Test

9. Rare Disease Genetic Testing Market, by Technology

  • 9.1. Microarray
  • 9.2. Next Generation Sequencing
    • 9.2.1. Sequencing By Ligation
    • 9.2.2. Sequencing By Synthesis
  • 9.3. Polymerase Chain Reaction
    • 9.3.1. Digital PCR
    • 9.3.2. Quantitative PCR

10. Rare Disease Genetic Testing Market, by Disease Indication

  • 10.1. Hematological Disorders
  • 10.2. Metabolic Disorders
    • 10.2.1. Enzyme Deficiencies
    • 10.2.2. Mitochondrial Disorders
  • 10.3. Neuromuscular Disorders
  • 10.4. Oncology

11. Rare Disease Genetic Testing Market, by Application

  • 11.1. Carrier Screening
  • 11.2. Diagnostics
  • 11.3. Newborn Screening
  • 11.4. Prenatal Screening
    • 11.4.1. Invasive
    • 11.4.2. Non Invasive
  • 11.5. Research Applications

12. Rare Disease Genetic Testing Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Research Institutions
  • 12.4. Specialty Clinics

13. Rare Disease Genetic Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Rare Disease Genetic Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Rare Disease Genetic Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Rare Disease Genetic Testing Market

17. China Rare Disease Genetic Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3billion, Inc.
  • 18.6. Ambry Genetics Corporation
  • 18.7. Arup Laboratories
  • 18.8. Baylor Genetics
  • 18.9. Caris Life Sciences
  • 18.10. CENTOGENE N.V.
  • 18.11. Color Health, Inc.
  • 18.12. F. Hoffmann-La Roche Ltd.
  • 18.13. Fulgent Genetics, Inc.
  • 18.14. GeneDx, LLC
  • 18.15. Genomelink, Inc.
  • 18.16. Helix OpCo, LLC
  • 18.17. Illumina, Inc.
  • 18.18. Integrated DNA Technologies, Inc.
  • 18.19. Invitae Corporation
  • 18.20. Laboratory Corporation Of America Holdings
  • 18.21. Macrogen, Inc.
  • 18.22. Myriad Genetics, Inc.
  • 18.23. Nonacus Limited
  • 18.24. OPKO Health, Inc.
  • 18.25. PerkinElmer Inc.
  • 18.26. Progenity, Inc.
  • 18.27. QIAGEN N.V.
  • 18.28. Quest Diagnostics Incorporated
  • 18.29. Realm IDX, Inc.
  • 18.30. Sanofi S.A.
  • 18.31. The Cooper Companies, Inc.
  • 18.32. Thermo Fisher Scientific Inc.
  • 18.33. Variantyx, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CLINICAL EXOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CLINICAL EXOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CLINICAL EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH EXOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH EXOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TARGETED GENOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TARGETED GENOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TARGETED GENOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SINGLE GENE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SINGLE GENE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SINGLE GENE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY LIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY LIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY LIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENZYME DEFICIENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENZYME DEFICIENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENZYME DEFICIENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 257. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 259. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 262. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 266. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE,